BRUSSELS, Belgium and CAMBRIDGE, Mass. – June 12, 2025 –

比利时布鲁塞尔和美国马萨诸塞州剑桥市——2025年6月12日——

UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint.

优时比（Euronext布鲁塞尔：UCB）和百健公司（NASDAQ：BIIB）今天公布了来自PHOENYCS GO 3期研究的更多详细结果，该研究评估了dapirolizumab pegol（DZP），一种新型无Fc片段的抗CD40L候选药物。在研究中，DZP在患有中度至重度系统性红斑狼疮（SLE）的患者中显示出显著的临床疾病活动改善，主要终点为第48周基于英国群岛狼疮评估组（BILAG）的复合狼疮评估（BICLA）。

Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology’s annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide.

在其他临床指标上也观察到了改善，包括疲劳和疾病活动/缓解。这些结果在西班牙巴塞罗那举行的欧洲风湿病学协会联盟（EULAR）2025年年会上公布。DZP在系统性红斑狼疮（SLE）中的安全性和有效性尚未确立，且尚未获得任何全球监管机构批准用于治疗SLE。

A second Phase 3 trial of dapirolizumab pegol is ongoing with the goal of confirming the results from PHOENYCS GO..

达匹罗立单抗聚乙二醇的第二项 III 期临床试验正在进行中，目标是确认 PHOENYCS GO 的结果。

“Despite being a common manifestation of systemic lupus erythematosus, fatigue is a difficult-to-treat symptom that can severely impact a person’s quality of life, and remains a challenge to address,” said Ioannis Parodis, MD, PhD, Associate Professor of Rheumatology, Karolinska University Hospital, Sweden.

“尽管疲劳是系统性红斑狼疮的常见表现，但作为一种难以治疗的症状，它可能严重影响患者的生活质量，仍然是一个亟待解决的挑战，”瑞典卡罗林斯卡大学医院风湿病学副教授Ioannis Parodis医学博士表示。

“The results we observed in this Phase 3 study indicate that participants treated with dapirolizumab pegol have the potential to achieve consistent improvements in fatigue beyond the current standard of care.” .

“我们在第三阶段研究中观察到的结果表明，接受达匹罗珠单抗聚乙二醇治疗的参与者有潜力在疲劳方面实现比目前标准护理更为显著的持续改善。”

In an analysis of the impact of DZP on patient-reported fatigue in people with SLE participating in the PHOENYCS GO study, individuals receiving DZP in addition to standard of care (SOC) treatment demonstrated improvements across two fatigue measurements:

在分析DZP对参与PHOENYCS GO研究的SLE患者自我报告疲劳的影响时，接受DZP加标准治疗（SOC）的个体在两项疲劳测量中均显示出改善：

Improvements in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scores were greater in the DZP group (change from baseline, 8.9), compared with SOC alone (5.2; nominal* p=0.0024) at Week 48.

与单独使用SOC（5.2；名义*p=0.0024）相比，DZP组在慢性病治疗功能评估（FACIT）-疲劳评分的改善更大（从基线变化为8.9），在第48周时。

Using FATIGUE-PRO, a measure recently developed to capture the patient experience of fatigue in SLE, greater improvements from baseline (nominal* p<0.05) were observed in people receiving DZP compared with SOC alone in the Physical Fatigue (change from baseline difference between groups,7.6), Mental and Cognitive (5.6), and Susceptibility to Fatigue (7.8) scales at Week 48. .

使用FATIGUE-PRO（一种最近开发的用于捕捉SLE患者疲劳体验的测量工具），在第48周时，接受DZP治疗的患者相较于单独接受SOC治疗的患者，在身体疲劳（组间基线变化差异为7.6）、精神与认知疲劳（5.6）以及疲劳易感性（7.8）量表上观察到较基线更大的改善（名义*p<0.05）。

“Being able to address both fatigue and remission are areas of critical unmet need in lupus care, an important treatment goal is to improve the quality of life for patients as well as to reduce the long-term risk of organ damage through disease remission,” said Eric F. Morand, MBBS, Head of the Monash Health Rheumatology Unit, Monash University, Australia.

“能够同时解决疲劳和缓解问题，是狼疮护理中尚未满足的关键需求。一个重要治疗目标是改善患者的生活质量，并通过疾病缓解来降低器官损伤的长期风险，”澳大利亚莫纳什大学莫纳什健康风湿病科主任埃里克·F·莫兰德（Eric F. Morand）表示。

“In the PHOENYCS GO study, dapirolizumab pegol has shown meaningful impact in helping patients achieve remission and low disease activity, offering the exciting possibility for improved disease control while reducing exposure to glucocorticoids. Dapirolizumab pegol has the potential to become a significant new medication for people living with SLE, as shown by the breadth of effect seen in the study and I look forward to seeing results from the second Phase 3 study.”.

“在PHOENYCS GO研究中，聚乙二醇化达匹罗利珠单抗显示出帮助患者实现缓解和降低疾病活动度的显著效果，为改善疾病控制同时减少糖皮质激素暴露提供了令人兴奋的可能性。达匹罗利珠单抗有潜力成为系统性红斑狼疮（SLE）患者的重要新药，这从研究中观察到的广泛疗效可见一斑，我期待看到第二项III期研究的结果。”

In an additional analysis, improvements were seen on measures of low disease activity, as measured by Low Lupus Disease Activity State (LLDAS) and disease remission, as measured by Definition of Remission in SLE (DORIS). Both measures include assessments of disease activity, in addition to a required low dose glucocorticoid intake (<7.5 mg prednisone / day in LLDAS; <5 mg prednisone / day in DORIS)..

在额外的分析中，低疾病活动度指标有所改善，这些指标由低狼疮疾病活动状态（LLDAS）和系统性红斑狼疮缓解定义（DORIS）衡量。这两项指标均包括对疾病活动度的评估，并要求低剂量糖皮质激素摄入（LLDAS中为<7.5毫克泼尼松/天；DORIS中为<5毫克泼尼松/天）。

At Week 48, the percentage of participants achieving low disease activity in the DZP group was twice that of the SOC only group (40.9% and 19.6%, respectively; nominal* p<0.0001). As early as Week 12, greater proportions of participants receiving DZP plus SOC achieved LLDAS versus SOC alone (nominal* p<0.05). .

在第48周，DZP组中达到低疾病活动度的参与者比例是仅SOC组的两倍（分别为40.9%和19.6%；名义*p<0.0001）。早在第12周，接受DZP加SOC治疗的参与者中有更高比例达到了LLDAS，相较于单独使用SOC（名义*p<0.05）。

23.6% of participants receiving DZP plus SOC achieved low disease activity in ≥50% of visits through 48 weeks compared with 15.9% receiving SOC alone (nominal* p=0.1042).

接受DZP加SOC的参与者中有23.6%在48周内≥50%的随访中达到低疾病活动度，而单独接受SOC的参与者为15.9%（名义*p=0.1042）。

A higher proportion of those receiving DZP (19.2%) versus SOC alone (8.4%) also achieved DORIS at Week 48 (nominal* p=0.0056).

接受DZP治疗的患者（19.2%）相较于仅接受SOC治疗的患者（8.4%）在第48周时也达到了DORIS（名义*p=0.0056）。

* Having met the primary endpoint, improvement of moderate-to-severe disease activity as assessed by achievement of BICLA after 48 weeks and the key secondary endpoint having a p-value = 0.1776, all subsequent secondary and tertiary endpoints are descriptive and nominal p-values are included.

* 已达到主要终点，即在48周后通过实现BICLA评估的中重度疾病活动性的改善，并且关键次要终点的p值=0.1776，所有后续的次要和三级终点均为描述性，且包含名义p值。

The safety profile of DZP was generally favorable. The safety results were consistent with previous DZP studies and with that in study participants with SLE receiving an immunomodulator. A higher proportion of individuals receiving DZP plus SOC had treatment-emergent adverse events (TEAEs) compared to SOC alone (82.6% vs.

DZP的安全性总体良好。安全性结果与之前的DZP研究一致，也与接受免疫调节剂的SLE研究参与者的结果一致。与单独使用SOC相比，接受DZP加SOC的个体出现治疗相关不良事件（TEAEs）的比例较高（82.6% vs.）。

75.0%). The proportion of participants with serious TEAEs was 9.9% in participants receiving DZP plus SOC was lower as compared to 14.8% in those receiving SOC alone. Discontinuation of treatment or study participation due to TEAEs occurred in 4.7% (10) of participants receiving DZP plus SOC and 3.7% (4) of participants receiving SOC alone. .

75.0%）。在接受DZP加SOC治疗的参与者中，出现严重TEAEs的比例为9.9%，低于单独接受SOC治疗的参与者（14.8%）。因TEAEs而停止治疗或研究参与的情况，在接受DZP加SOC的参与者中有4.7%（10人），在接受单独SOC治疗的参与者中有3.7%（4人）。

Participants from the PHOENYCS GO study (NCT04294667) will continue to be followed in a long-term open-label study. A second Phase 3 trial of dapirolizumab pegol, PHOENYCS FLY (

PHOENYCS GO 研究 (NCT04294667) 的参与者将继续在一项长期开放标签研究中接受随访。Dapirolizumab pegol 的第二项 III 期试验 PHOENYCS FLY (

NCT06617325

NCT06617325

) is ongoing.

）正在进行中。

About Systemic Lupus Erythematosus (SLE)

关于系统性红斑狼疮（SLE）

SLE is a chronic, multifactorial autoimmune disease that is caused by the activation of autoreactive T, B and antigen-presenting cells, resulting in manifestations across multiple organ systems with periods of illness or flares alternating with periods of inactivity.

系统性红斑狼疮（SLE）是一种慢性、多因素的自身免疫性疾病，由自反应性T细胞、B细胞和抗原呈递细胞的激活引起，导致多个器官系统出现病变，疾病活动期或病情加重与非活动期交替出现。

1

1

SLE can present itself in several ways including rash, arthritis, anemia, thrombocytopenia, serositis, nephritis, seizures or psychosis.

系统性红斑狼疮可以通过多种方式表现，包括皮疹、关节炎、贫血、血小板减少症、浆膜炎、肾炎、癫痫发作或精神病。

2

2

SLE is associated with a greater risk of death from causes such as infection and cardiovascular disease.

系统性红斑狼疮与因感染和心血管疾病等导致的死亡风险增加相关。

An estimated 90% of people living with lupus are women; most begin to see symptoms between the ages of 15-55.

据估计，90%的红斑狼疮患者为女性，大多数人在15至55岁之间开始出现症状。

3,4,5

3，4，5

Individuals from populations of African, Hispanic, Asian and Native American descent are at a greater risk of earlier onset and more aggressive disease.

非洲、西班牙裔、亚洲和美洲原住民群体的个体面临更大的早发和更严重疾病风险。

6,7

6,7

Pregnancy in women with SLE is high risk, with higher maternal and fetal mortality and morbidity than the general population.

系统性红斑狼疮（SLE）女性患者的妊娠属于高危情况，其孕产妇和胎儿的死亡率及发病率均高于普通人群。

8,9

8,9

About dapirolizumab pegol

关于dapirolizumab pegol

Dapirolizumab pegol is a novel investigational humanized Fc-free polyethylene glycol (PEG)-conjugated antigen-binding (Fab’) fragment. Dapirolizumab pegol inhibits CD40L signaling which has been shown to reduce B cell activation and autoantibody production, mitigate type 1 interferon (IFN) secretion, and attenuate T cell and antigen-presenting cell (APC) activation..

Dapirolizumab pegol是一种新型的研究性人源化无Fc聚乙二醇（PEG）结合的抗原结合（Fab'）片段。Dapirolizumab pegol抑制CD40L信号传导，已证明可减少B细胞活化和自身抗体产生，减轻1型干扰素（IFN）分泌，并减弱T细胞和抗原呈递细胞（APC）的活化。

10

10

Dapirolizumab pegol is presently in Phase 3 clinical development for the treatment of systemic lupus erythematosus (SLE) under a collaboration between UCB and Biogen.

Dapirolizumab pegol 目前在UCB与Biogen合作下，正处于治疗系统性红斑狼疮（SLE）的第三阶段临床开发中。

11

11

For further information, contact UCB:

如需更多信息，请联系UCB：

Investor Relations

投资者关系

Antje Witte

安特耶·维特

T +32.2.559.94.14

电话：+32.2.559.94.14

email antje.witte@ucb.com

电子邮件：antje.witte@ucb.com

Corporate Communications

企业传播

Laurent Schots

劳伦特·肖茨

T +32.2.559.92.64

电话：+32.2.559.92.64

email laurent.schots@ucb.com

电子邮件：laurent.schots@ucb.com

Brand Communications

品牌传播

Adriaan Snauwaert

阿德里安·斯瑙瓦特

T +32 497 70 23 46

电话：+32 497 70 23 46

email adriaan.snauwaert@ucb.com

电子邮件：adriaan.snauwaert@ucb.com

For further information, contact Biogen:

有关更多信息，请联系百健：

Media Relations

媒体关系

Jack Cox

杰克·考克斯

+ 1 781 464 3260

+1 781 464 3260

public.affairs@biogen.com

公共事务@biogen.com

Investor Relations

投资者关系

Chuck Triano

查克·特里亚诺

+1 781 464 2442

+1 781 464 2442

IR@biogen.com

IR@biogen.com

About UCB

关于UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €6.1 billion in 2024.

优时比（UCB），比利时布鲁塞尔（www.ucb.com），是一家全球生物制药公司，专注于发现和开发创新药物与解决方案，以改变免疫系统或中枢神经系统严重疾病患者的生活。公司在约40个国家拥有约9,000名员工，并在2024年实现了61亿欧元的收入。

UCB is listed on Euronext Brussels (symbol: UCB). .

UCB在布鲁塞尔泛欧交易所上市（股票代码：UCB）。

About Biogen

关于百健公司

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes.

成立于1978年的Biogen是一家领先的生物技术公司，致力于开创创新科学以提供新药物，改变患者生活，并为股东和我们的社区创造价值。我们深入理解人体生物学，并利用不同模式推进首创的治疗方案或疗法，以实现卓越的治疗效果。

Our approach is to take bold risks, balanced with return on investment to deliver long-term growth..

我们的方法是大胆冒险，同时平衡投资回报，以实现长期增长。

The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow us on social media - Facebook, LinkedIn, X, YouTube.

公司定期在其网站 www.biogen.com 上发布可能对投资者重要的信息。请在社交媒体上关注我们：Facebook、LinkedIn、X、YouTube。

Forward looking statements UCB

前瞻性声明 UCB

This document contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management.

本文件包含前瞻性陈述，包括但不限于包含“潜在”、“相信”、“预期”、“预计”、“打算”、“计划”、“寻求”、“估计”、“可能”、“将”、“继续”等词语和类似表达的陈述。这些前瞻性陈述基于管理层当前的计划、估计和信念。

All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results.

所有声明，除历史事实声明之外，均可被视为前瞻性声明，包括收入、营业利润率、资本支出、现金、其他财务信息、预期法律、仲裁、政治、监管或临床结果或实践以及其他此类估计和结果。

By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document.

由于此类前瞻性陈述的性质，其并不能保证未来的表现，并且受到已知和未知的风险、不确定性以及假设的影响，这些因素可能导致UCB的实际结果、财务状况、业绩或成就，或行业结果，与本文件中包含的此类前瞻性陈述所明示或暗示的任何未来结果、业绩或成就存在重大差异。

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, .

可能导致此类差异的重要因素包括但不限于：战争、流行病和恐怖主义的全球传播及其影响、总体地缘政治环境、气候变化、总体经济、商业和竞争状况的变化、无法获得必要的监管批准或在可接受的条件或预期时间内获得批准、与研究和开发相关的成本、UCB在研或开发中产品前景的变化、未来司法裁决或政府调查的影响、安全性、质量、数据完整性或生产问题。

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise.

鉴于这些不确定性，公众被提醒不要对这些前瞻性声明给予任何过度依赖。这些前瞻性声明仅在本文档的日期作出，并不反映上述不断演变的事件或风险以及任何其他不利因素的潜在影响，除非另有说明。

The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB..

公司继续认真跟进事态发展，以评估这些事件对UCB的财务重要性（如有）。

UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations..

UCB明确表示，除非适用法律法规要求，否则不承担更新本文件中任何前瞻性声明的义务，无论该等声明是为了确认实际结果，还是为了报告或反映与其相关的任何变化，或任何该等声明所基于的事件、条件或情况的任何变化。

Biogen Safe Harbor

百健安全港

This press release contains forward-looking statements, relating to: our strategy and plans; potential of, and expectations for, our commercial business and pipeline programs; capital allocation and investment strategy; clinical development programs, clinical trials, and data readouts and presentations; regulatory discussions, submissions, filings, and approvals; the potential benefits, safety, and efficacy of our and our collaboration partners’ products and investigational therapies; the anticipated benefits and potential of investments,  actions to improve risk profile and productivity of R&D pipeline, collaborations, and business development activities; and our future financial and operating results.

本新闻稿包含前瞻性陈述，涉及：我们的战略和计划；我们商业业务和研发管线项目的潜力与预期；资本配置和投资策略；临床开发项目、临床试验以及数据公布和展示；监管讨论、提交、申报和批准；我们及合作方产品和在研疗法的潜在益处、安全性和有效性；投资的预期收益和潜力；改善研发管线风险状况和生产力的行动、合作及业务发展活动；以及我们未来的财务和运营结果。

These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would,” and other words and terms of similar meaning.

这些前瞻性陈述可能伴随诸如“目标”、“预期”、“假设”、“相信”、“考虑”、“继续”、“可能”、“估计”、“预计”、“预测”、“目的”、“指导”、“希望”、“意图”、“或许”、“客观”、“展望”、“计划”、“可能”、“潜力”、“预测”、“预计”、“前景”、“应该”、“目标”、“将”、“会”等具有类似含义的词语和术语。

Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval.

药物开发和商业化涉及高度风险，只有少数研发项目能够成功实现产品的商业化。早期临床试验的结果可能无法全面反映后期或更大规模临床试验的完整结果，并且不能确保获得监管批准。

You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. This press release includes, among others, forw.

您不应过分依赖这些陈述。鉴于其前瞻性，这些陈述涉及重大风险和不确定性，可能基于不准确的假设，并可能导致实际结果与这些陈述中反映的结果有重大差异。本新闻稿包括但不限于向前看的陈述。

We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, factors relating to: our substantial dependence on revenue from our products and other payments under licensing, collaboration, acquisition or divestiture agreements; uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; the successful execution of our strategic and growth initiatives, including acquisitions; the drivers for growing our business; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks associated with current and potential future healthcare reforms; risks related to commercialization of biosimilars, which is sub.

我们提醒您，这些声明受到风险和不确定性的约束，其中许多是我们无法控制的，可能导致未来事件或结果与此文件中所述或暗示的内容有重大差异，包括但不限于以下相关因素：我们对来自产品的收入以及其他根据许可、合作、收购或剥离协议支付的款项存在重大依赖；在开发、授权或许可其他候选产品或为现有产品增加适应症方面的长期成功的不确定性；与产品批准、现有产品新增适应症批准、销售、定价、增长、报销以及已上市和研发中产品上市相关的预期、计划和前景；生物制药和医疗保健行业以及其他我们所参与市场竞争加剧可能带来的影响，包括来自新原创疗法、仿制药、前药和现有产品的生物类似药以及通过简化监管途径获批产品的竞争加剧；我们有效实施公司战略的能力；成功执行我们的战略和增长计划，包括收购；推动我们业务增长的因素；在获取和维持对我们产品的充分覆盖范围、定价和报销方面遇到的困难；推动我们业务增长的因素，包括我们对合作伙伴和其他第三方在产品开发、监管批准、商业化以及其他业务方面的依赖，而这些均不在我们的完全控制之下；与当前和潜在未来医疗改革相关的风险；与生物类似药商业化相关的风险，这属于部分内容。

These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected.

这些声明仅截至本新闻稿发布之日，并基于我们目前可获得的信息和估计。如果已知或未知的风险或不确定性成为现实，或者基本假设被证明不准确，实际结果可能与过去的结果以及预期、估计或预测的结果存在重大差异。

Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned “Note Regarding Forward-Looking Statements” and “Item 1A.

投资者应注意不要过分依赖前瞻性陈述。更多风险、不确定性和其他事项的列表和描述，请参阅我们截至2024年12月31日财年的年度报告Form 10-K，以及我们随后的Form 10-Q和Form 10-K报告，每份报告中均包含标题为“关于前瞻性陈述的说明”和“项目1A”的部分。

Risk Factors,” and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise..

风险因素”，以及我们随后在 Form 8-K 上的报告。除非法律要求，我们不承担任何公开更新前瞻性陈述的义务，无论这是由于新信息、未来事件、情况变化或其他原因。

References

参考文献

Tselios K, Gladman DD, Touma Z, et al. Disease course patterns in systemic lupus erythematosus. Lupus. 2019;28(1):114-122.

Tselios K, Gladman DD, Touma Z, 等。系统性红斑狼疮的病程模式。《狼疮》。2019;28(1):114-122。

Fanouriakis A, Tziolos N, Bertsias G, et al. Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80(1):14-25. doi:10.1136/annrheumdis-2020-218272

Fanouriakis A, Tziolos N, Bertsias G, 等。系统性红斑狼疮的诊断与管理更新。《风湿病年鉴》。2021；80（1）：14-25。doi:10.1136/annrheumdis-2020-218272

Petri M. Epidemiology of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2002;16(5):847-58. Epub 2002/12/11. doi: 10.1053/berh.2002.0259. PubMed PMID: 12473278.

Petri M. 系统性红斑狼疮的流行病学。《最佳实践与研究：临床风湿病学》。2002；16（5）：847-58。在线发表于2002年12月11日。doi: 10.1053/berh.2002.0259。PubMed PMID: 12473278。

Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. Ann Rheum Dis. 2016;75(1):136-41. Epub 2014/10/01. doi: 10.1136/annrheumdis-2014-206334. PubMed PMID: 25265938; PubMed Central PMCID: PMCPMC4717400.

里斯 F、多尔蒂 M、格雷因 M、达文波特 G、拉尼翁 P、张 W。1999-2012年英国系统性红斑狼疮的发病率和患病率。《风湿病年鉴》。2016；75（1）：136-41。电子出版日期 2014/10/01。doi：10.1136/annrheumdis-2014-206334。PubMed PMID：25265938；PubMed Central PMCID：PMCPMC4717400。

Pons-Estel GJ, Ugarte-Gil MF, Alarcón GS. Epidemiology of systemic lupus erythematosus. Expert Rev Clin Immunol. 2017;13(8):799-814.

Pons-Estel GJ, Ugarte-Gil MF, Alarcón GS. 系统性红斑狼疮的流行病学。《专家评论：临床免疫学》。2017;13(8):799-814。

Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016;12(10):605-20. Epub 2016/08/26. doi: 10.1038/nrrheum.2016.137. PubMed PMID: 27558659.

卡特 EE，巴尔 SG，克拉克 AE。系统性红斑狼疮的全球负担：患病率、健康差异与社会经济影响。《自然评论风湿病学》。2016年；12（10）：605-20。电子出版日期：2016/08/26。doi：10.1038/nrrheum.2016.137。PubMed PMID：27558659。

Kheir JM, Guthridge CJ, Johnston JR, Adams LJ, Rasmussen A, Gross TF, et al. Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000247. Epub 2018/03/14. doi: 10.1136/lupus-2017-000247. PubMed PMID: 29531773; PubMed Central PMCID: PMCPMC5844376..

Kheir JM, Guthridge CJ, Johnston JR, Adams LJ, Rasmussen A, Gross TF, 等。美洲原住民系统性红斑狼疮患者的独特临床特征、自身抗体及药物使用。《狼疮科学与医学》。2018;5(1):e000247。电子出版日期 2018/03/14。doi: 10.1136/lupus-2017-000247。PubMed PMID: 29531773；PubMed Central PMCID: PMCPMC5844376。

Mehta B, Luo Y, Xu J, Sammaritano L, Salmon J, Lockshin M, et al. Trends in Maternal and Fetal Outcomes Among Pregnant Women With Systemic Lupus Erythematosus in the United States: A Cross-sectional Analysis. Ann Intern Med. 2019;171(3):164-71. Epub 2019/07/10. doi: 10.7326/M19-0120. PubMed PMID: 31284305..

Mehta B, Luo Y, Xu J, Sammaritano L, Salmon J, Lockshin M, 等。美国系统性红斑狼疮孕妇的母婴结局趋势：一项横断面分析。《内科学年鉴》。2019；171（3）：164-71。在线发表于2019/07/10。doi: 10.7326/M19-0120。PubMed PMID: 31284305。

Bitencourt N, Bermas BL. Pharmacological Approach to Managing Childhood-Onset Systemic Lupus Erythematosus During Conception, Pregnancy and Breastfeeding. Paediatr Drugs.

Bitencourt N, Bermas BL。儿童期发病的系统性红斑狼疮在受孕、妊娠和哺乳期间的药物管理方法。《儿科药物》。

Furie RA, Bruce IN, Dörner T, et al. Phase 2 randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate to severe active systemic lupus erythematosus (SLE). Rheumatology (Oxford).2021;60(11): 5397-407.

Furie RA, Bruce IN, Dörner T, 等。Dapirolizumab pegol 治疗中至重度活动性系统性红斑狼疮（SLE）的二期随机、安慰剂对照试验。《风湿病学（牛津）》2021；60(11): 5397-407。

Clinicaltrials.gov (NCT04294667). A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (PHOENYCS GO) 2023 [cited August 2024] Available at: https://clinicaltrials.gov/ct2/show/NCT04294667. Retrieved July 25, 2024..

Clinicaltrials.gov (NCT04294667)。一项评估Dapirolizumab Pegol在中重度活动性系统性红斑狼疮研究参与者中的疗效和安全性的研究（PHOENYCS GO）2023 [引用日期为2024年8月]。可在以下网址获取：https://clinicaltrials.gov/ct2/show/NCT04294667。检索日期为2024年7月25日。